Prolactinomas usually lead to infertility and medical treatment restores fertility. Prolactinoma size might increase during pregnancy (2.1% for microprolactinomas and 21% for macroprolactinomas). In this review article, multiple aspects of prolactinomas care during and before pregnancy were discussed. Dopamine agonists are the treatment of choice, if indicated during pregnancy (cabergoline and bromocriptine, while quinagolide is not recommended). It is recommended to stop dopamine agonists in patients with microprolactinoma during pregnancy and follow the patients for mass effect symptoms and visual disturbances every trimester. Dopamine agonists could be stopped as well in patient with intra-seller macroprolactinomas with more frequent clinical follow ups during pregnancy. Magnetic resonance imaging (MRI) without contrast is indicated for patients suspected to have tumor enlargement. Dopamine agonists (cabergoline or bromocriptine) are the treatment of choice for invasive/metastatic macroprolactinomas during pregnancy, and neurosurgery is rarely indicated.

No abstract

Graves' disease (GD) is an autoimmune thyroid disease, which is considered the most common cause of primary hyperthyroidism. GD usually manifests with symptoms such as tremors, palpitations, heat intolerance, weight loss, and specific signs on physical examination (proptosis and pretibial myxedema). However, systemic involvement is also recognized, for example, hepatic involvement in patients with GD may range from asymptomatic laboratory findings of liver function derangement (either transaminases elevations or intrahepatic cholestasis) up to hepatic failure. We describe a rare case of Graves' thyrotoxicosis presenting with severe cholestasis and non-parathyroid hormone-related hypercalcemia. An extensive evaluation for hepatobiliary causes of cholestasis, including hepatic biopsy, was entirely negative. The patient was successfully treated with methimazole with subsequent clinical and biochemical improvement.

No abstract